Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) insider Jeanette Bjorkquist sold 727 shares of the firm's stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $19.62, for a total transaction of $14,263.74. Following the sale, the insider owned 17,673 shares in the company, valued at $346,744.26. This trade represents a 3.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Assembly Biosciences Stock Performance
Shares of ASMB opened at $19.92 on Wednesday. The firm has a market cap of $405.57 million, a P/E ratio of 19.13 and a beta of 1.26. Assembly Biosciences, Inc. has a twelve month low of $19.25 and a twelve month high of $39.71. The firm's 50 day moving average price is $25.54 and its two-hundred day moving average price is $27.12.
Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.52. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%. The company had revenue of $13.37 million during the quarter, compared to the consensus estimate of $8.60 million. On average, sell-side analysts anticipate that Assembly Biosciences, Inc. will post 2.28 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on the company. HC Wainwright reiterated a "buy" rating and set a $50.00 target price on shares of Assembly Biosciences in a report on Tuesday, August 18th. UBS Group dropped their price target on Assembly Biosciences from $52.00 to $48.00 and set a "buy" rating on the stock in a research note on Tuesday. Weiss Ratings restated a "sell (d-)" rating on shares of Assembly Biosciences in a report on Thursday, October 15th. Zacks Research raised Assembly Biosciences from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 20th. Finally, Mizuho set a $53.00 price objective on Assembly Biosciences in a report on Tuesday, September 1st. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $46.50.
Check Out Our Latest Stock Analysis on ASMB
Institutional Trading of Assembly Biosciences
Hedge funds and other institutional investors have recently made changes to their positions in the business. Janus Henderson Group PLC raised its holdings in shares of Assembly Biosciences by 1.4% in the first quarter. Janus Henderson Group PLC now owns 849,309 shares of the biopharmaceutical company's stock valued at $23,479,000 after purchasing an additional 11,384 shares during the last quarter. Seven Fleet Capital Management LP lifted its position in shares of Assembly Biosciences by 671.5% in the second quarter. Seven Fleet Capital Management LP now owns 433,147 shares of the biopharmaceutical company's stock worth $11,903,000 after purchasing an additional 377,000 shares in the last quarter. Stempoint Capital LP boosted its holdings in Assembly Biosciences by 18.3% during the first quarter. Stempoint Capital LP now owns 185,435 shares of the biopharmaceutical company's stock worth $5,146,000 after purchasing an additional 28,707 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in Assembly Biosciences by 4.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 39,446 shares of the biopharmaceutical company's stock worth $1,095,000 after purchasing an additional 1,634 shares during the last quarter. Finally, Squarepoint Ops LLC boosted its holdings in Assembly Biosciences by 43.7% during the second quarter. Squarepoint Ops LLC now owns 34,214 shares of the biopharmaceutical company's stock worth $940,000 after purchasing an additional 10,410 shares during the last quarter. 19.92% of the stock is currently owned by institutional investors and hedge funds.
Key Stories Impacting Assembly Biosciences
Here are the key news stories impacting Assembly Biosciences this week:
- Neutral Sentiment: UBS lowered its price target to $48 from $52 but kept its Buy rating, leaving a favorable recommendation alongside a more cautious valuation. UBS price target update
- Neutral Sentiment: CEO Jason Okazaki and three other insiders sold shares, but the reported sales were to cover tax withholding on vested equity awards—rather than identified open-market sales. The transactions may draw attention but provide limited evidence of a change in company outlook. CEO SEC filing
- Neutral Sentiment: Assembly Biosciences said senior management will participate in one-on-one meetings and present at investor conferences in November; no new business or clinical update was announced. Conference announcement
About Assembly Biosciences
(
Get Free Report)
Assembly Biosciences, Inc is a clinical-stage biotechnology company focused on developing oral therapeutics for serious viral infections. The company's research programs target chronic hepatitis B virus (HBV) infection and herpesvirus infections, including herpes simplex virus (HSV), with the goal of addressing diseases for which existing treatments may not provide adequate cures or long-term control.
Assembly's pipeline includes novel antiviral candidates designed to interfere with essential stages of viral replication.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
